Caricamento...

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel

The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design of VDA–chemotherapy combination treatments. This study examined the antitumour activity of ZD6126, a microtubul...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Martinelli, M, Bonezzi, K, Riccardi, E, Kuhn, E, Frapolli, R, Zucchetti, M, Ryan, A J, Taraboletti, G, Giavazzi, R
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2007
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360417/
https://ncbi.nlm.nih.gov/pubmed/17848949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603969
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !